NK VUE ELISA Insert (CE) |
|
NK VUE Tube Insert (CE) |
|
[NK Vue] Cross-Sectional and Time-Dependent Analyses on Inflammatory Markers following Natural Killer Cell Activity. (Diagnostics. 2022) |
|
[NK Vue] Prognostic value of natural killer cell activity for patients with HER2+ advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. (Cancer Immunol Immunother. 2021) |
|
[NK Vue] Changes in natural killer cell activity after surgery and predictors of its recovery-failure. (J Surg Oncol. 2021) |
|
[SuperNK] A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer |
|
Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation. (Int J Mol Sci. 2020) |
|
Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy. (J Formos Med Assoc. 2020) |
|
Impact of Smoking on Human Natural Killer Cell Activity: A Large Cohort Study. (J Cancer Prev. 2020) |
|
Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non Small Cell Lung Cancer. (Target Oncol. 2020) |
|
Natural Killer Cell Function Tests by Flowcytometry-Based Cytotoxicity and IFN-γ Production for the Diagnosis of Adult Hemophagocytic Lymphohistiocytosis. (Int J Mol Sci. 2019) |
|
Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. (Cancer Epidemiol. 2019) |
|
Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. (Transl Oncol. 2019) |
|
Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study. (Onco Targets Ther. 2019) |
|
Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. (J Diabetes Investig. 2019) |
|